Soligenix, Inc. (SNGX) Investor Relations Documents

Soligenix, Inc. (SNGX) investor relations documents from the company's IR site: 1 presentation, 8 press releases; latest deck 2020-09-09. Read in-app with summaries. First-party data.

Advantages of the CiVax™ Program for Development of a Broadly Distributed Heat Stable COVID-19 Vaccine: Soligenix (NASDAQ: SNGX) is a biopharmaceutical company developing CiVax, a thermostable protein-based COVID-19 vaccine candidate using CoVaccine HT adjuvant.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-07Press releasePress release
2026-06-08Press releaseSoligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine
2026-05-26Press releaseSuitability of Vaccine Platform for Bundibugyo Virus, Cause of the Ebola Outbreak in Congo
2026-05-08Press releaseSoligenix Announces Recent Updates and First Quarter 2026 Financial Results
2026-04-28Press releaseSoligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell L
2026-04-02Press releasePositive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cuta
2025-12-18Press releasePress release
2025-12-17Press releaseSoligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Mode
2020-09-09PresentationAdvantages of the CiVax™ Program for Development of a Broadly Distributed Heat Stable COVID-19 Vaccine

SNGX overview · SNGX earnings · SNGX financials · SNGX KPIs · SNGX ownership · SNGX peers · SNGX filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.